$ALZN

Alzamend Neuro, Inc.

CIK:0001677077|SEC Filings

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Jul. 31, 2026	Jul. 31, 2025
OPERATING EXPENSES
Research and development	$ 1,085,998	$ 1,740,867
General and administrative	1,939,398	959,334
Total operating expenses	3,025,396	2,700,201
Loss from operations	(3,025,396)	(2,700,201)
OTHER EXPENSE, NET
Interest income	399
Interest expense	(2,005)	(2,483)
Total other expense, net	(1,606)	(2,483)
NET LOSS	$ (3,027,002)	$ (2,702,684)
Basic net loss per common share	$ (0.68)	$ (1.28)
Diluted net loss per common share	$ (0.68)	$ (1.28)
Basic weighted average common shares outstanding	4,478,709	2,106,036
Diluted weighted average common shares outstanding	4,478,709	2,106,036

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Jul. 31, 2026	Jul. 31, 2025
Cash flows from operating activities:
Net loss	$ (3,027,002)	$ (2,702,684)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	27,685	27,685
Stock-based compensation to employees, directors and consultants	77,199	42,902
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	390,372	(79,239)
Accounts payable and accrued liabilities	1,393,229	348,550
Net cash used in operating activities	(1,138,517)	(2,362,786)
Cash flows from financing activities:
Net proceeds from the issuance of common stock	669,272
Net proceeds from the issuance of preferred stock, net	7,350,000	4,035,000
Net cash provided by financing activities	8,019,272	4,035,000
Net increase in cash	6,880,755	1,672,214
Cash at beginning of period	710,689	3,948,658
Cash at end of period	7,591,444	5,620,872
Non-cash financing activities:
Conversion of Series B convertible preferred stock to common stock		564,755
Conversion of Series C convertible preferred stock to common stock		$ 5,757,176

Condensed Balance Sheets (Unaudited) - USD ($)	Jul. 31, 2026	Apr. 30, 2026
CURRENT ASSETS
Cash	$ 7,591,444	$ 710,689
Prepaid expenses and other current assets	663,436	1,053,808
TOTAL CURRENT ASSETS	8,254,880	1,764,497
Property, plant and equipment, net	287,181	314,866
TOTAL ASSETS	8,542,061	2,079,363
CURRENT LIABILITIES
Accounts payable and accrued liabilities	2,739,381	1,346,152
TOTAL LIABILITIES, ALL CURRENT	2,739,381	1,346,152
STOCKHOLDERS’ EQUITY
Series D Convertible Preferred Stock, $0.0001 par value, $1,000 stated value per share, 25,000 and 0 nil shares designated; 7,500 and 0 nil issued and outstanding as of July 31, 2026 and April 30, 2026, respectively	1
Common stock, $0.0001 par value: 300,000,000 shares authorized; 4,825,723 and 4,256,039 issued and outstanding as of July 31, 2026 and April 30, 2026, respectively	482	425
Additional paid-in capital	76,136,842	68,040,429
Accumulated deficit	(70,334,645)	(67,307,643)
TOTAL STOCKHOLDERS’ EQUITY	5,802,680	733,211
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 8,542,061	$ 2,079,363